Kenneth J Shea

US Patent:

6417236, Jul 9, 2002

Filed:

Jun 1, 2001

Appl. No.:

09/872097

Inventors:

Stephen T. Hobson - Belcamp MD
Ernest H. Braue - Whiteford MD
Kenneth Shea - Irvine CA

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC
The Regents of the University of California - Oakland CA

International Classification:

A61K 3102

US Classification:

514759, 424 59, 514723, 514772, 514789, 514844, 514845, 514937, 514939, 514944

Abstract:

A topical skin protectant formulation containing a barrier cream and an active hybrid organic-inorganic polysilsesquioxane material for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

US Patent:

6525154, Feb 25, 2003

Filed:

Jul 20, 2001

Appl. No.:

09/910451

Inventors:

Kenneth J. Shea - Irvine CA
Bradley R. Hart - Irvine CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C08F12054

US Classification:

5263072, 526172, 526199, 526217, 526220, 5262381, 526306

Abstract:

Molecularly imprinted polymers (MIPs) wherein the template comprises either a) a peptide or amino acid sequence that has an N-terminal histidine residue or b) histamine. The MIPs may be prepared in aqueous systems using reagents that are water soluble at the relevant concentrations. Also, the invention includes methods for using the MIPs as receptors or adsorbents for, or to determine the present or non-presence of, target molecules containing i) particular peptides or amino acid sequences having N-terminal histidine residue or ii) histamine.

US Patent:

7211192, May 1, 2007

Filed:

Mar 29, 2002

Appl. No.:

10/112573

Inventors:

Kenneth J. Shea - Irvine CA, US
Stephen T. Hobson - Gunpowder MD, US
Joseph Tran - San Diego CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

B01D 11/00

US Classification:

210634, 210640, 210660, 210690

Abstract:

The present invention relates generally to hybrid organic-inorganic adsorbents for decontamination of fluids. Bridged poysilsesquioxanes are a family of hybrid organic-inorganic materials prepared by sol-gel processing of monomers that contain a variable organic bridging group and two or more trifunctional silyl groups. Specifically, the present invention relates to dipropylenedisulfide-co-phenylene-bridged polysilsesquioxane compositions, methods of making dipropylenedisulfide-co-phenylene-bridged polysilsesquioxanes, and methods of use of dipropylenedisulfide-co-phenylene-bridged polysilsesquioxanes. The present invention discloses properties of dipropylenedisulfide-co-phenylene-bridged polysilsesquioxanes that include high ligand loading, increased surface area, and increased porosity. These properties make dipropylenedisulfide-co-phenylene-bridged polysilsesquioxanes excellent adsorbents for decontamination of fluids for use in environmental and industrial processes.

US Patent:

20040242542, Dec 2, 2004

Filed:

Mar 25, 2004

Appl. No.:

10/810497

Inventors:

Kenneth Shea - Irvine CA, US
Carl Wagner - Irvine CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K031/69
A61K031/66
A61K031/505
A61K031/445

US Classification:

514/064000, 514/319000, 514/408000, 514/553000, 514/114000

Abstract:

Small molecule analogues of 1-aminoadamantane and methods for using such compositions to induce CD81-dependent antiproliferative effects and/or for the treatment of disorders of human or veterinary patients and/or for the manufacture of therapeutic preparations used to treat such disorders.

US Patent:

20070203341, Aug 30, 2007

Filed:

Apr 26, 2007

Appl. No.:

11/740804

Inventors:

Kenneth Shea - Irvine CA, US
Stephen Hobson - Gunpowder MD, US
Joseph Tran - San Diego CA, US

International Classification:

C07F 7/02
C07D 307/02
C07D 333/02

US Classification:

546014000, 549029000, 549429000, 556433000

Abstract:

The present invention relates generally to hybrid organic-inorganic adsorbents for decontamination of fluids. Bridged poysilsesquioxanes are a family of hybrid organic-inorganic materials prepared by sol-gel processing of monomers that contain a variable organic bridging group and two or more trifunctional silyl groups. Specifically, the present invention relates to dipropylenedisulfide-co-phenylene-bridged polysilsesquioxane compositions, methods of making dipropylenedisulfide-co-phenylene-bridged polysilsesquioxanes, and methods of use of dipropylenedisulfide-co-phenylene-bridged polysilsesquioxanes. The present invention discloses properties of dipropylenedisulfide-co-phenylene-bridged polysilsesquioxanes that include high ligand loading, increased surface area, and increased porosity. These properties make dipropylenedisulfide-co-phenylene-bridged polysilsesquioxanes excellent adsorbents for decontamination of fluids for use in environmental and industrial processes.

US Patent:

20070244326, Oct 18, 2007

Filed:

Mar 23, 2007

Appl. No.:

11/690475

Inventors:

Kenneth Shea - Irvine CA, US
Douglas Loy - Tucson AZ, US
Lihua Zhao - Sunnyvale CA, US

International Classification:

C07F 7/02

US Classification:

546014000

Abstract:

In some embodiments, the present invention is directed to a method for chemically modifying 7-substituted coumarins to produce polymerizable monomers that are used to prepare photoresponsive materials. In one embodiment, 7-hydroxy-coumarin (umbelliferone) is so modified. The present invention also relates to the photoresponsive linear polymers, copolymers, and hybrid network materials produced from the polymerizable monomers, and the method for their preparation.

US Patent:

20100003204, Jan 7, 2010

Filed:

Jul 2, 2009

Appl. No.:

12/459541

Inventors:

Douglas Anson Loy - Tucson AZ, US
Kenneth J. Shea - Irvine CA, US
Dylan J. Boday - Tucson AZ, US
Jason T. Wertz - Tucson AZ, US

Assignee:

Energy Materials Corporation - Livermore CA

International Classification:

A61K 8/02
C01B 33/12

US Classification:

424 59, 423335

Abstract:

The invention discloses and claims a new class of chemical compositions with ideal sunscreen properties. The chemical composition comprises spherical particles between 200 nm and 10 microns in diameter prepared by an emulsion polymerization of tetraalkoxysilanes or organotrialkoxysilanes or organobridged trialkoxysilanes with a dye monomer bearing two or more alkoxysilyl groups attached to the bridging chromophore. The resulting spheres absorb ultraviolet light. The dye can be any organic chromophore capable of receiving multiple trialkoxysilyl groups resulting in multipoint covalent attachment that precludes leaching of the dye from the spheres. The formic acid-toluene-monomer emulsion polymerization allows for large-scale (>100 gram) synthesis of monodisperse particles under acidic, non-aqueous conditions without surfactants. The particles less than 1 micron in diameter are smooth as talc to the touch and will provide a smooth formulation for sunscreen creams or lotions.

US Patent:

20120097613, Apr 26, 2012

Filed:

Jan 11, 2010

Appl. No.:

13/144027

Inventors:

Yu Hoshino - Irvine CA, US
Kenneth J. Shea - Irvine CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

B01D 15/08
C08K 5/41
C08F 8/00
C07K 1/14
C08B 37/00

US Classification:

210660, 530415, 5361231, 525 55, 525 541, 525 542, 525296, 524156

Abstract:

The present invention relates to imprinted polymer nanoparticles. In particular, the present invention provides imprinted polymer nanopaticles polymerized in the presence of a target molecule (e.g., peptide), wherein the imprinted polymer nanoparticles comprise vinyl, acryl, and/or methacryl monomers, wherein the monomers have affinity for the target molecule. The present invention also relates to methods of using imprinted polymer nanoparticles in biomoacromolecular purification methods (e.g., to purify monoclonal antibodies or hormones), in toxin elimination methods (e.g., hemoperfusion), in diagnostics, in research, as well as in therapeutic methods (e.g., therapeutic methods where antisera or monoclonal antibodies are normally employed).